 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 GLOBE NEWSWIRE -- Harpoon Therapeutics, Inc. NASDAQ: HARP, a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN217 clinical program presented at the 64th American Society of Hematology ASH Annual Meeting and provide a corporate update. 